Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $518.19K rose 4.3% year over year, ahead of the -26.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +3.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $518.19K-20.7% QoQ
- Last fiscal yearDec 2025
- $2.23M+3.4% YoY
- LTMMar 2026
- $2.36M-26.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.3% | -100.0% | -104.3 pp |
| 1 year | +3.4% | -100.0% | -103.4 pp |
| 3-year CAGR | +12.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 2.23M USD
- Year-over-year change
- +3.4%
- 4-year CAGR
- +21.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.23M | +3.4% |
| FY2024 | 2024-12-31 | 2.15M | +32.2% |
| FY2023 | 2023-12-31 | 1.63M | +4.1% |
| FY2022 | 2022-12-31 | 1.56M | +50.7% |
| FY2021 | 2021-12-31 | 1.04M | — |
Selling, General & Admin vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.5% is the 7th highest of 9, against a peer median of -1.7%.
- Over three fiscal years its annual growth of +12.5% compares with a peer median of +2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $45.53M USD | -35.6% | -12.4% | 36.8% | |
| LTM Mar 2026 | $40.57M USD | -24.5% | -6.8% | 269.8% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $21.57M USD | +8.6% | +44.6% | 180.0% |
| LTM Mar 2026 | CA$18.6M CAD | +58.0% | +35.4% | — | |
| LTM Mar 2026 | $18.36M USD | +21.1% | -6.5% | 244.9% | |
| LTM Mar 2026 | $15.81M USD | +34.6% | +50.4% | — | |
| LTM Mar 2026 | $10.32M USD | -12.0% | -7.1% | — | |
| LTM Mar 2026 | $3.55M USD | -47.4% | +11.8% | — | |
| LTM Mar 2026 | $2.36M USD | -26.5% | +12.5% | — | |
| Peer median (excluding GLSI) | — | -1.7% | +2.7% | 212.5% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Gross Profit | (3.61K) | (3.61K) | (3.61K) | (3.61K) | (1.78K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.56M | 6.48M | 7.7M | 15.48M | 17.22M |
| Selling, General & Admin | 1.04M | 1.56M | 1.63M | 2.15M | 2.23M |
| Operating Expenses | 4.59M | 8.04M | 9.32M | 17.63M | 19.45M |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| EBITDA | (4.57M) | (7.82M) | (8.89M) | (17.41M) | (19.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.6M) | (8.04M) | (9.33M) | (17.64M) | (19.45M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Income Before Tax | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| EPS (Diluted) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| Weighted Avg Shares | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
| Weighted Avg Shares (Diluted) | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.